Status:
UNKNOWN
Safety of Ertapenem in Beta-lactam Allergic Patients.
Lead Sponsor:
Catholic University of the Sacred Heart
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
IgE-Mediated Hypersensitivity
Allergy
Eligibility:
All Genders
16-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to at least one beta-lactam molecule.
Detailed Description
Ertapenem is a new carbapenem, stable to dehydropeptidase which has a broad antibacterial activity. Ertapenem exhibits a bactericidal mode of action and it has a long half-life of 4.5 hours; for this ...
Eligibility Criteria
Inclusion
- IgE-mediated allergy to at least one beta-lactam molecule
Exclusion
- positive allergy testing to ertapenem
- chronic diseases
- treatment with beta-blockers
- pregnancy
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01159379
Start Date
January 1 2011
End Date
December 1 2011
Last Update
January 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergy Department, Catholic University of the Sacred Heart
Rome, Italy, 00168